

CITATION REPORT

List of articles citing

Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hyper

DOI: 10.1161/circgenetics.111.961888

Circulation: Cardiovascular Genetics, 2012, 5, 336-43.

Source: <https://exaly.com/paper-pdf/52365975/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
317	Pulmonary vascular disease in mice xenografted with human BM progenitors from patients with pulmonary arterial hypertension. 2012 , 120, 1218-27		61
316	The molecular genetics and cellular mechanisms underlying pulmonary arterial hypertension. 2012 , 2012, 106576		11
315	Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress. 2012 , 4, 58		56
314	A novel channelopathy in pulmonary arterial hypertension. 2013 , 369, 351-361		311
313	Pulmonale Hypertonie. 2013 , 10, 53-57		
312	Updated clinical classification of pulmonary hypertension. 2013 , 62, D34-41		1937
311	Relevant issues in the pathology and pathobiology of pulmonary hypertension. 2013 , 62, D4-12		379
310	Pediatric pulmonary hypertension. 2013 , 62, D117-26		357
309	Pulmonary arterial hypertension. 2013 , 8, 97		168
308	Epidemiology of pulmonary arterial hypertension. 2013 , 15, 638-49		15
307	Pediatric pulmonary arterial hypertension. 2013 , 15, 606-13		4
306	The next-generation sequencing revolution and its impact on genomics. 2013 , 155, 27-38		655
305	Genetics of pulmonary arterial hypertension. 2013 , 34, 651-63		7
304	Genetic mechanisms of atrial fibrillation: impact on response to treatment. 2013 , 10, 317-29		60
303	TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension. 2013 , 50, 500-6		115
302	Elevated pulmonary arterial pressure and altered expression of Ddah1 and Arg1 in mice lacking cavin-1/PTRF. 2013 , 1, e00008		26
301	Signal transduction in the development of pulmonary arterial hypertension. 2013 , 3, 278-93		61

300	Nitrosation-dependent caveolin 1 phosphorylation, ubiquitination, and degradation and its association with idiopathic pulmonary arterial hypertension. 2013 , 3, 816-30	45
299	The first Keystone Symposia Conference on pulmonary vascular disease and right ventricular dysfunction: Current concepts and future therapies. 2013 , 3, 275-7	2
298	Autosomal dominant spondylocostal dysostosis is caused by mutation in TBX6. 2013 , 22, 1625-31	70
297	The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations. 2013 , 22, 3667-79	77
296	Circulation Editors' Picks. 2013 , 128,	
295	Circulation Editors' Picks. 2013 , 127,	
294	Heritable forms of pulmonary arterial hypertension. 2013 , 34, 568-80	19
293	Update on pediatric pulmonary arterial hypertension. Differences and similarities to adult disease. 2013 , 77, 2639-50	15
292	Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary arterial hypertension. 2014 , 189, 1110-20	14
291	Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension. 2014 , 189, 1260-72	58
290	Mutations of NOTCH3 in childhood pulmonary arterial hypertension. 2014 , 2, 229-39	37
289	Somatic mosaicism in ACVRL1 with transmission to several offspring affected with severe pulmonary arterial hypertension. 2014 , 164A, 2121-3	5
288	KCNK3: new gene target for pulmonary hypertension?. 2014 , 8, 385-7	19
287	Progress in the diagnosis and management of pulmonary hypertension in children. 2014 , 26, 527-35	11
286	Genetics of pulmonary hypertension. 2014 , 29, 520-7	31
285	Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways. 2014 , 2014, 24-36	11
284	The genetic basis of pulmonary arterial hypertension. 2014 , 133, 471-9	62
283	Exome sequencing greatly expedites the progressive research of Mendelian diseases. 2014 , 8, 42-57	35

282	Targeted therapies in pulmonary arterial hypertension. 2014 , 141, 172-91	128
281	The promise of whole-exome sequencing in medical genetics. 2014 , 59, 5-15	310
280	An evidence-based knowledgebase of pulmonary arterial hypertension to identify genes and pathways relevant to pathogenesis. 2014 , 10, 732-40	14
279	[Pulmonary hypertension: definition, diagnostic and new classification]. 2014 , 43, 935-44	2
278	Emerging role of polymerase-1 and transcript release factor (PTRF/ Cavin-1) in health and disease. 2014 , 357, 505-13	15
277	Update in systemic sclerosis-associated pulmonary arterial hypertension. 2014 , 43, e293-304	20
276	The genetics of pulmonary arterial hypertension. 2014 , 115, 189-202	116
275	Pathogenesis of pulmonary hypertension: a case for caveolin-1 and cell membrane integrity. 2014 , 306, H15-25	41
274	Sex differences in the pulmonary circulation: implications for pulmonary hypertension. 2014 , 306, H1253-64	24
273	Current clinical management of pulmonary arterial hypertension. 2014 , 115, 131-147	48
272	Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension. 2014 , 19, 1241-5	22
271	News from the caves: update on the structure and function of caveolae. 2014 , 29, 99-106	63
270	Accurate genetic diagnosis of Finnish pulmonary arterial hypertension patients using oligonucleotide-selective sequencing. 2015 , 3, 354-62	5
269	Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. 2015 , 5, 435-65	154
268	Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. 2015 , 147, 1385-1394	26
267	Delineation of New Disorders and Phenotypic Expansion of Known Disorders Through Whole Exome Sequencing. 2015 , 3, 209-218	2
266	Myocardial tissue caveolae. 2015 , 5, 871-86	8
265	Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. 2015 , 36, 1113-27	142

264	Redox biology in pulmonary arterial hypertension (2013 Grover Conference Series). 2015 , 5, 599-609	16
263	Whole exome sequencing identifies de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. 2015 , 167A, 1796-806	49
262	Pulmonary capillary hemangiomatosis: a focus on the EIF2AK4 mutation in onset and pathogenesis. 2015 , 8, 181-8	9
261	A Frame-Shift Mutation in CAV1 Is Associated with a Severe Neonatal Progeroid and Lipodystrophy Syndrome. 2015 , 10, e0131797	27
260	Dexamethasone downregulates caveolin-1 causing muscle atrophy via inhibited insulin signaling. 2015 , 225, 27-37	17
259	Physiologie, Klassifikation, Pathologie und Pathophysiologie. 2015 , 12, 373-380	1
258	Cavin Family: New Players in the Biology of Caveolae. 2015 , 320, 235-305	31
257	A critical appraisal of the updated 2014 Nice Pulmonary Hypertension Classification System. 2015 , 31, 367-74	12
256	Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. 2015 , 191, 208-18	68
255	Novel nonsense mutation in the PTRF gene underlies congenital generalized lipodystrophy in a consanguineous Saudi family. 2015 , 58, 216-21	24
254	Congenital generalized lipodystrophies--new insights into metabolic dysfunction. 2015 , 11, 522-34	143
253	Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling. 2015 , 191, 1273-86	101
252	Between Rho(k) and a hard place: the relation between vessel wall stiffness, endothelial contractility, and cardiovascular disease. 2015 , 116, 895-908	120
251	Management of pulmonary arterial hypertension. 2015 , 65, 1976-97	229
250	Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension. 2015 , 290, 960-71	35
249	Building the case for novel clinical trials in pulmonary arterial hypertension. 2015 , 8, 114-23	14
248	Secondary Structure Analysis of a Functional Construct of Caveolin-1 Reveals a Long C-Terminal Helix. 2015 , 109, 1686-8	17
247	Caveolae protect endothelial cells from membrane rupture during increased cardiac output. 2015 , 211, 53-61	83

246	A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF- β cascades with restored caveolin-1 expression. 2015 , 41, 21-31	32
245	Assembly and Turnover of Caveolae: What Do We Really Know?. 2016 , 4, 68	17
244	High Frequency of Pulmonary Hypertension-Causing Gene Mutation in Chinese Patients with Chronic Thromboembolic Pulmonary Hypertension. 2016 , 11, e0147396	12
243	Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. 2016 , 17,	77
242	Transcriptome of the inner circular smooth muscle of the developing mouse intestine: Evidence for regulation of visceral smooth muscle genes by the hedgehog target gene, cJun. 2016 , 245, 614-26	8
241	Caveolae are involved in mechanotransduction during pulmonary hypertension. 2016 , 310, L1078-87	17
240	[Towards new targets for the treatment of pulmonary arterial hypertension : Importance of cell-cell communications]. 2016 , 210, 65-78	
239	Caveolin-1 is an aggresome-inducing protein. 2016 , 6, 38681	6
238	Complex inheritance in Pulmonary Arterial Hypertension patients with several mutations. 2016 , 6, 33570	12
237	Towards a molecular classification of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016 , 48, 987-989	13.6 2
236	Genetic analyses in a cohort of children with pulmonary hypertension. <i>European Respiratory Journal</i> , 2016 , 48, 1118-1126	13.6 54
235	Análisis de los genes BMPR2, TBX4 y KCNK3 y correlación genotipo-fenotipo en pacientes y familias españolas con hipertensión arterial pulmonar. 2016 , 69, 1011-1019	30
234	Identification of genetic defects in pulmonary arterial hypertension by a new gene panel diagnostic tool. 2016 , 130, 2043-2052	16
233	Contemporary diagnosis and management of pulmonary hypertension. 2016 , 102, 1680-91	3
232	Characterization of a caveolin-1 mutation associated with both pulmonary arterial hypertension and congenital generalized lipodystrophy. 2016 , 17, 1297-1312	32
231	Molecular Analysis of BMPR2, TBX4, and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension. 2016 , 69, 1011-1019	15
230	World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. 2016 , 34, 363-74	74
229	Genetic Insights into Pulmonary Arterial Hypertension. Application of Whole-Exome Sequencing to the Study of Pathogenic Mechanisms. 2016 , 194, 393-7	11

228	EIF2AK4 mutation as "second hit" in hereditary pulmonary arterial hypertension. 2016 , 17, 141		22
227	Shared gene expression patterns in mesenchymal progenitors derived from lung and epidermis in pulmonary arterial hypertension: identifying key pathways in pulmonary vascular disease. 2016 , 6, 483-497		16
226	MURC deficiency in smooth muscle attenuates pulmonary hypertension. 2016 , 7, 12417		15
225	Clinical Utility Gene Card for: Congenital Generalized Lipodystrophy. 2016 , 24,		3
224	Current progress in therapeutic agents for pulmonary arterial hypertension: new insights into their mechanisms of action from endothelin system. 2016 , 148, 231-238		
223	Increase in caveolae and caveolin-1 expression modulates agonist-induced contraction and store- and receptor-operated Ca(2+) entry in pulmonary arteries of pulmonary hypertensive rats. 2016 , 84, 55-66		14
222	Complex genetics of pulmonary diseases: lessons from genome-wide association studies and next-generation sequencing. 2016 , 168, 22-39		11
221	Reconciling paradigms of abnormal pulmonary blood flow and quasi-malignant cellular alterations in pulmonary arterial hypertension. 2016 , 83, 17-25		5
220	Caveolae: One Function or Many?. 2016 , 26, 177-189		157
219	Identification of Rare Variants in ATP8B4 as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing. 2016 , 68, 191-200		28
218	Genetic testing in pulmonary hypertension: how should our clinical practice reflect recent advances?. <i>European Respiratory Journal</i> , 2016 , 47, 388-9	13.6	1
217	Novel approaches to pulmonary arterial hypertension drug discovery. 2016 , 11, 407-14		4
216	Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. 2016 , 194, 464-75		52
215	Molecular pathogenesis and current pathology of pulmonary hypertension. 2016 , 21, 239-57		38
214	Genetic counselling in a national referral centre for pulmonary hypertension. <i>European Respiratory Journal</i> , 2016 , 47, 541-52	13.6	63
213	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. 2017 , 151, 468-480		57
212	Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing. 2017 , 195, 23-31		27
211	Discovery of a murine model of clinical PAH: Mission impossible?. 2017 , 27, 229-236		10

210	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. 2017 , 5, 125-134	76
209	Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor. 2017 , 56, 488-496	14
208	Pathophysiology and Genetics: BMPR2. 2017 , 115-124	
207	Biomechanical Strain Exacerbates Inflammation on a Progeria-on-a-Chip Model. 2017 , 13, 1603737	48
206	Mutations in BMPR2 are not present in patients with pulmonary hypertension associated with congenital diaphragmatic hernia. 2017 , 52, 1747-1750	3
205	First identification of mutation in heritable pulmonary arterial hypertension. 2017 , 131, 689-698	23
204	Identification of Biomarkers for Schistosoma-Associated Pulmonary Arterial Hypertension Based on RNA-Seq Data of Mouse Whole Lung Tissues. 2017 , 195, 377-385	4
203	Bone morphogenetic protein signalling in pulmonary hypertension: advances and therapeutic implications. 2017 , 102, 1083-1089	6
202	BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. 2017 , 74, 2979-2995	54
201	New genetic causes for complex hereditary spastic paraplegia. 2017 , 379, 283-292	11
200	Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension. 2017 , 7, 1923	12
199	Pulmonary arterial hypertension: Specialists' knowledge, practices, and attitudes of genetic counseling and genetic testing in the USA. 2017 , 7, 372-383	10
198	The caveolae dress code: structure and signaling. 2017 , 47, 117-125	88
197	Learning a Comorbidity-Driven Taxonomy of Pediatric Pulmonary Hypertension. 2017 , 121, 341-353	12
196	Prediction of marker genes associated with hypertension by bioinformatics analyses. 2017 , 40, 137-145	4
195	Caveolins and cavins in the trafficking, maturation, and degradation of caveolae: implications for cell physiology. 2017 , 312, C459-C477	58
194	Bone Morphogenetic Protein Signaling in Pulmonary Arterial Hypertension. 2017 , 293-326	
193	Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers. 2017 , 20, 490-504.e5	117

192	Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations. 2017 , 21, 181-190	27
191	Pulmonary Hypertension and Thrombembolism—Long-Term Management and Chronic Oral Anticoagulation. 2017 , 2, 727-741	
190	The Nitric Oxide Pathway in Pulmonary Vascular Disease. 2017 , 120, S71-S79	54
189	Genetics of Pulmonary Arterial Hypertension. 2017 , 38, 585-595	7
188	Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement. 2017 , 196, e32-e47	22
187	A disease-associated frameshift mutation in caveolin-1 disrupts caveolae formation and function through introduction of a de novo ER retention signal. 2017 , 28, 3095-3111	20
186	Heritable pulmonary hypertension: from bench to bedside. 2017 , 26,	17
185	Clinical Application of Genetic Testing in Heart Failure. 2017 , 14, 543-553	4
184	A burden of rare variants in BMPR2 and KCNK3 contributes to a risk of familial pulmonary arterial hypertension. 2017 , 17, 57	13
183	Genetics of pulmonary hypertension in the clinic. 2017 , 23, 386-391	9
182	The role of genetics in pulmonary arterial hypertension. 2017 , 241, 273-280	36
181	A systematic review of genetic mutations in pulmonary arterial hypertension. 2017 , 18, 82	45
180	Bone marrow transplantation prevents right ventricle disease in the -deficient mouse model of pulmonary hypertension. 2017 , 1, 526-534	6
179	The Role of Caveolin 1 in HIV Infection and Pathogenesis. 2017 , 9,	15
178	Whole-exome sequencing improves genetic testing accuracy in pulmonary artery hypertension. 2018 , 8, 2045894018763682	2
177	Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. 2018 , 27,	13
176	Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults. 2018 , 11, e001887	65
175	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. 2018 , 9, 1416	182

174	CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation. 2018 , 116, 41-56	20
173	Caveolins as Regulators of Stress Adaptation. 2018 , 93, 277-285	8
172	Rare variants in RNF213, a susceptibility gene for moyamoya disease, are found in patients with pulmonary hypertension and aggravate hypoxia-induced pulmonary hypertension in mice. 2018 , 8, 2045894018778155	20
171	Pulmonary arterial hypertension: pathogenesis and clinical management. 2018 , 360, j5492	312
170	Genetics in pulmonary arterial hypertension in a large homogeneous Japanese population. 2018 , 94, 70-80	9
169	OBSOLETE: Pulmonary Hypertension. 2018 ,	
168	CAV1 regulates primordial follicle formation via the Notch2 signalling pathway and is associated with premature ovarian insufficiency in humans. 2018 , 33, 2087-2095	7
167	Caveolin and Endothelial NO Signaling. 2018 , 82, 257-279	13
166	Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?. 2018 , 19,	45
165	Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension. 2018 , 19,	32
164	A Review of Transcriptome Analysis in Pulmonary Vascular Diseases. 2018 , 1783, 259-277	4
163	Pulmonary Arterial Hypertension. 2018 , 14, 255-269	40
162	Pulmonary Hypertension. 2018 , 204-222	
161	Using Omics to Understand and Treat Pulmonary Vascular Disease. 2018 , 5, 157	8
160	Pulmonary Arterial Hypertension. 2018 , 181-194	
159	Genetic analyses in a cohort of 191 pulmonary arterial hypertension patients. 2018 , 19, 87	15
158	Three-dimensional spatial analysis of missense variants in RTEL1 identifies pathogenic variants in patients with Familial Interstitial Pneumonia. 2018 , 19, 18	6
157	Exome data clouds the pathogenicity of genetic variants in Pulmonary Arterial Hypertension. 2018 , 6, 835-844	3

156	Identification of genetic factors underlying persistent pulmonary hypertension of newborns in a cohort of Chinese neonates. 2019 , 20, 174	9
155	Endosomes and Autophagy: Regulators of Pulmonary Endothelial Cell Homeostasis in Health and Disease. 2019 , 31, 994-1008	11
154	Sudden death of a preschool child diagnosed by postmortem examination. 2019 , 66, 144-146	
153	Evaluation and classification of pulmonary arterial hypertension. 2019 , 11, S1789-S1799	17
152	Cytokines trigger disruption of endothelium barrier function and p38 MAP kinase activation in -silenced human lung microvascular endothelial cells. 2019 , 9, 2045894019883607	7
151	A tip of the CAP1 to cholesterol metabolism. 2020 , 41, 253-254	3
150	A Combined Targeted and Whole Exome Sequencing Approach Identified Novel Candidate Genes Involved in Heritable Pulmonary Arterial Hypertension. 2019 , 9, 753	13
149	Pulmonary Hypertension and ATP-Sensitive Potassium Channels. 2019 , 74, 14-22	14
148	United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. 2019 , 9, 2045894019851696	5
147	Genetic linkage analysis of a large family identifies as a candidate modulator of reduced penetrance in heritable pulmonary arterial hypertension. 2019 , 56, 481-490	1
146	Role of BRCA1-associated protein (BRAP) variant in childhood pulmonary arterial hypertension. 2019 , 14, e0211450	2
145	The worldwide mutational landscape of Berardinelli-Seip congenital lipodystrophy. 2019 , 781, 30-52	15
144	A Bayesian Network Approach to Disease Subtype Discovery. 2019 , 1939, 299-322	1
143	New pathogenic variant of BMPR2 in pulmonary arterial hypertension. 2019 , 29, 462-466	1
142	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). 2019 , 83, 842-945	67
141	Injury-Induced Shedding of Extracellular Vesicles Depletes Endothelial Cells of Cav-1 (Caveolin-1) and Enables TGF- β -Dependent Pulmonary Arterial Hypertension. 2019 , 39, 1191-1202	20
140	Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension. 2019 , 11, 69	45
139	Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure. 2019 , 10, 125-170	39

138	TGF β and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension. 2019 , 24, 703-716		43
137	Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	37
136	Germline mutation causes idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	56
135	Pulmonary Hypertension. 2019 , 327-341.e9		
134	Association of the gene polymorphisms of and their interactions with the risk of essential hypertension in the Chinese Han population. 2019 , 39,		0
133	Low-grade albuminuria in pulmonary arterial hypertension. 2019 , 9, 2045894018824564		6
132	Genetics and genomics of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	179
131	Upregulation of SERT and ADORA1 in broilers with acute right ventricular failure. 2019 , 125, 397-400		2
130	Molecular genetic framework underlying pulmonary arterial hypertension. 2020 , 17, 85-95		86
129	Characterization of Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. 2020 , 201, 575-585		46
128	Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium. 2020 , 6, 9-22		11
127	Expression of a Human Caveolin-1 Mutation in Mice Drives Inflammatory and Metabolic Defect-Associated Pulmonary Arterial Hypertension. 2020 , 7, 540		1
126	Idiopathic pulmonary arterial hypertension in a pot-bellied pig (<i>Sus scrofa domesticus</i>) with right-sided congestive heart failure. 2020 , 31, 1-7		
125	DNA Damage and Repair in Pulmonary Arterial Hypertension. 2020 , 11,		6
124	Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension. 2020 , 10, 2045894020957234		3
123	At the X-Roads of Sex and Genetics in Pulmonary Arterial Hypertension. 2020 , 11,		0
122	'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension. 2020 , 11,		3
121	Identification of the Novel Variants in Patients With Chronic Thromboembolic Pulmonary Hypertension. 2020 , 9, e015902		5

120	Endogenous and Inhaled Nitric Oxide for the Treatment of Pulmonary Hypertension. 2020,	
119	Endothelial Basement Membrane Components and Their Products, Matrikines: Active Drivers of Pulmonary Hypertension?. 2020, 9,	14
118	Caveolae and Lipid Rafts in Endothelium: Valuable Organelles for Multiple Functions. 2020, 10,	11
117	Bayesian Inference Associates Rare Variants with Specific Phenotypes in Pulmonary Arterial Hypertension. 2020,	9
116	TBX4 variants and pulmonary diseases: getting out of the 'Box'. 2020, 26, 277-284	3
115	The Genetic Epidemiology of Pediatric Pulmonary Arterial Hypertension. 2020, 225, 65-73.e5	8
114	The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient. 2020, 9,	13
113	Comprehensive identification of signaling pathways for idiopathic pulmonary arterial hypertension. 2020, 318, C913-C930	3
112	Cholesterol: A Novel Regulator of Vasoreactivity in Pulmonary Arteries. 2020, 62, 671-673	
111	Pulmonary Hypertension Remodels the Genomic Fabrics of Major Functional Pathways. 2020, 11,	5
110	Familial pulmonary arterial hypertension by heterozygous loss of function. <i>European Respiratory Journal</i> , 2020, 55,	13.6 23
109	Altered Lipid Domains Facilitate Enhanced Pulmonary Vasoconstriction after Chronic Hypoxia. 2020, 62, 709-718	3
108	Association of Rare PTGIS Variants With Susceptibility and Pulmonary Vascular Response in Patients With Idiopathic Pulmonary Arterial Hypertension. 2020, 5, 677-684	12
107	Caveolin-1, a master regulator of cellular senescence. 2020, 39, 397-414	12
106	Transcriptomic analysis of pulmonary artery smooth muscle cells identifies new potential therapeutic targets for idiopathic pulmonary arterial hypertension. 2020, 177, 3505-3518	7
105	United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics. 2021, 159, 311-327	7
104	Genetic Delivery and Gene Therapy in Pulmonary Hypertension. 2021, 22,	3
103	Potential Cellular Targets Associated with the Signaling of the Pulmonary Hypertension. 2021, 435-445	

102	Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?. 2021 , 9,	17
101	Screening of key biomarkers and immune infiltration in Pulmonary Arterial Hypertension via integrated bioinformatics analysis. 2021 , 12, 2576-2591	6
100	Metabolism in Pulmonary Hypertension. 2021 , 83, 551-576	13
99	Identifying Potential Mutations Responsible for Cases of Pulmonary Arterial Hypertension. 2021 , 14, 113-124	0
98	Deficiency of cold-inducible RNA-binding protein exacerbated monocrotaline-induced pulmonary artery hypertension through Caveolin1 and CAVIN1. 2021 , 25, 4732-4743	1
97	Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension. 2021 , 10,	4
96	Integrative Omics to Characterize and Classify Pulmonary Vascular Disease. 2021 , 42, 195-205	1
95	Prognostic Significance of Systemic Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Idiopathic Pulmonary Hypertension. 2021 , 17, 77-93	2
94	Pulmonary Hypertension in Pregnancy: A Review. 2021 , 57,	1
93	Type I interferon activation and endothelial dysfunction in caveolin-1 insufficiency-associated pulmonary arterial hypertension. 2021 , 118,	1
92	Novel and Variants Are Implicated in the Pathogenesis of Pulmonary Arterial Hypertension. 2021 , 8, 625763	5
91	Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. 2021 , 13, 80	11
90	Sex Dimorphism in Pulmonary Hypertension: The Role of the Sex Chromosomes. 2021 , 10,	2
89	Pyrrolizidine alkaloid-induced transcriptomic changes in rat lungs in a 28-day subacute feeding study. 2021 , 95, 2785-2796	0
88	Ion channels as convergence points in the pathology of pulmonary arterial hypertension. 2021 , 49, 1855-1865	2
87	Mediation role of body fat distribution (FD) on the relationship between CAV1 rs3807992 polymorphism and metabolic syndrome in overweight and obese women. 2021 , 14, 202	2
86	A modified density gradient proteomic-based method to analyze endolysosomal proteins in cardiac tissue. 2021 , 24, 102949	0
85	Endothelial PHD2 Deficiency Induces Nitrate Stress via Suppression of Caveolin-1 in Pulmonary Arterial Hypertension.	0

84	Critical Role of Caveolin-1 Loss/Dysfunction in Pulmonary Hypertension. 2021 , 9,	0
83	Potassium (K) channels in the pulmonary vasculature: Implications in pulmonary hypertension Physiological, pathophysiological and pharmacological regulation. 2021 , 225, 107835	8
82	Endothelial cells in the pathogenesis of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021 , 58,	13.6 30
81	Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group. 2021 , 1-24	
80	Epidemiology of Pediatric Pulmonary Hypertension. 2014 , 2123-2137	2
79	Pulmonary Arterial Hypertension and Oxidative Stress. 2014 , 259-325	1
78	Historical Perspective on the Classification and Nomenclature of Pulmonary Hypertension. 2016 , 3-15	1
77	Pathogenesis of Pulmonary Arterial Hypertension. 2017 , 385-401	0
76	Caveolin-1 Regulation of Endothelial Nitric Oxide Synthase (eNOS) Function and Oxidative Stress in the Endothelium. 2014 , 1343-1363	6
75	Aberrant caveolin-1-mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension. 2017 , 28, 1177-1185	16
74	Bayesian inference associates rare KDR variants with specific phenotypes in pulmonary arterial hypertension.	3
73	Rare variant analysis of 4,241 pulmonary arterial hypertension cases from an international consortium implicate FBLN2, PDGFD and rare de novo variants in PAH.	4
72	Structure and assembly of CAV1 8S complexes revealed by single particle electron microscopy.	1
71	Novel risk genes and mechanisms implicated by exome sequencing of 2,572 individuals with pulmonary arterial hypertension.	2
70	Structure and assembly of CAV1 8S complexes revealed by single particle electron microscopy. 2020 , 6,	8
69	Novel Molecular Mechanisms of Pulmonary Hypertension: A Search for Biomarkers and Novel Drug Targets-From Bench to Bed Site. 2020 , 2020, 7265487	10
68	Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension. 2017 , 195, 292-301	32
67	What lipodystrophies teach us about the metabolic syndrome. 2019 , 129, 4009-4021	49

66	The 6th World Symposium on Pulmonary Hypertension: what's old is new. 2019 , 8,	49
65	Mutation in BMPR2 Promoter: A 'Second Hit' for Manifestation of Pulmonary Arterial Hypertension?. 2015 , 10, e0133042	20
64	The role of genomics and genetics in pulmonary arterial hypertension. 2020 , 2020, e202013	3
63	Classification of Pulmonary Hypertension. 2014 , 13, 17-20	1
62	New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension. 2019 , 26, 2844-2864	11
61	Customized Massive Parallel Sequencing Panel for Diagnosis of Pulmonary Arterial Hypertension. 2020 , 11,	10
60	Pulmonary hypertension and metabolic syndrome: Possible connection, PPAR α and Caveolin-1. 2014 , 6, 692-705	10
59	Enhanced caveolin-1 expression in smooth muscle cells: Possible prelude to neointima formation. 2015 , 7, 671-84	8
58	Loss of cavin1 and expression of p-caveolin-1 in pulmonary hypertension: Possible role in neointima formation. 2019 , 9, 17-29	1
57	Gene Mutation Annotation and Pedigree for Pulmonary Arterial Hypertension Patients in Han Chinese Patients.. 2021 , 16, 70	
56	Chasing Pulmonary Hypertension: 1980-2012. 2012 , 11, 121-123	
55	Pathogenic Mechanisms of Pulmonary Hypertension. 2014 , 1-32	
54	Molecular Biological Aspects, Therapeutic Targets and New Treatment Strategies. 2015 , 37-80	
53	Pathogenesis of Pulmonary Arterial Hypertension. 2015 , 37-65	
52	Pathogenic Mechanisms of Pulmonary Hypertension. 2015 , 4079-4104	
51	Solving the Measurement Problem and then Steppin' Out over the Line Riding the Rarest Italian: Crossing the Streams to Retrieve Stable Bioactivity in Majorana Bound States of Dialyzed Human Platelet Lysates. 2015 , 9, 32-44	
50	Epidemiology of Pulmonary Hypertension: From Quaternary Referral Centre to the Community. 2016 , 63-79	
49	Genetics of Pulmonary Vascular Disease. 2016 , 105-121	

48	Physiological and Pathological Consequences of Vascular BMP Signaling. 2017 , 367-407	
47	Architecture g�n�tique de l'hypertension pulmonaire : des g�nes aux m�dicaments. 2017 , 201, 879-893	
46	Identification of novel rare sequence variation underlying heritable pulmonary arterial hypertension.	
45	Pulmonary Vascular Diseases: Pulmonary Hypertension and HHT�What Are the Roles of Genetic Factors in the Pathogenesis of Pulmonary Vascular Diseases?. 2018 , 161-167	
44	OBSOLETE: Pulmonary Arterial Hypertension. 2018 ,	
43	Current Clinical Management and Basic Research in Pediatric Pulmonary Hypertension. 2019 , 35, 136-152	
42	Gender and Race Disparities in Pulmonary Hypertension Diagnosis and Treatment. 2020 , 195-202	
41	Epidemiology of Pediatric Pulmonary Hypertension. 2020 , 1-17	
40	Nanobulges: A Duplex Nanosystem for Multidimensional Applications. 2020 , 16, 668-675	0
39	Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics. 2015 , 67, 169-85	5
38	Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension.. 2022 , 17, 13	1
37	Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-�Superfamily Signaling.. 2021 , 8, 814222	1
36	Molecular basis of the association between transcription regulators nuclear respiratory factor 1 and inhibitor of DNA binding protein 3 and the development of microvascular lesions.. 2022 , 141, 104337	
35	Pulmonary Arterial Hypertension.. 2021 , 385, 2361-2376	27
34	Signal Transduction during Metabolic and Inflammatory Reprogramming in Pulmonary Vascular Remodeling.. 2022 , 23,	0
33	Molecular architecture of the human caveolin-1 complex.	1
32	Genomics of Pulmonary Hypertension. 2021 , 20, 142-149	
31	An Emerging Class of New Therapeutics Targeting TGF, Activin and BMP Ligands in Pulmonary Arterial Hypertension.. 2022 ,	

30	Polychlorinated Biphenyls and Pulmonary Hypertension.. 2022 , 19,	
29	Data_Sheet_1.pdf. 2020 ,	
28	Image_1.jpg. 2020 ,	
27	Image_2.jpg. 2020 ,	
26	Image_3.jpg. 2020 ,	
25	Image_4.jpg. 2020 ,	
24	Molecular architecture of the human caveolin-1 complex.. 2022 , 8, eabn7232	2
23	New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis.. 2022 , 130, 1365-1381	3
22	Classificaçã da hipertensã pulmonar. 2014 , 6-15	
21	Structural characterization of a breast cancer-associated mutation in caveolin-1.	0
20	The Role of EBP50 in Regulating Endothelial-To-Mesenchymal Transition in Pulmonary Hypertension.	
19	The Impact of Socioeconomic, Racial, and Ethnic Disparities on Pulmonary Hypertension Diagnosis and Treatment. 2022 , 21, 30-34	
18	Case Report: Caveolin-1 Associated with Severe (Pediatric-onset) Presentation of Pulmonary Arterial Hypertension..	0
17	Endothelial PHD2 deficiency induces nitrative stress via suppression of caveolin-1 in pulmonary hypertension. <i>European Respiratory Journal</i> , 2102643	13.6 1
16	Molecular Pathways in Pulmonary Arterial Hypertension. 2022 , 23, 10001	1
15	New progress in diagnosis and treatment of pulmonary arterial hypertension. 2022 , 17,	0
14	Defining the Clinical Validity of Genes Reported to Cause Pulmonary Arterial Hypertension.	0
13	Caveolin-1 rs1997623 variant and adult metabolic syndromeAssessing the association in three ethnic cohorts of Arabs, South Asians and South East Asians. 13,	0

12	Recent Advances in the Treatment of Pulmonary Arterial Hypertension. 2022 , 15, 1277	3
11	Design principles of caveolins across metazoa and beyond.	0
10	The Role of Bone Morphogenetic Protein Receptor Type 2 (BMPR2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling. 2022 , 11, 3823	0
9	Pathophysiology and Pathogenic Mechanisms of Pulmonary Hypertension: Role of Membrane Receptors, Ion Channels and Ca ²⁺ Signaling.	1
8	Pursuing Functional Biomarkers in Complex Disease: Focus on Pulmonary Arterial Hypertension. 2022 ,	0
7	Vascular pathobiology of pulmonary hypertension. 2022 ,	0
6	The Cavin-1/Caveolin-1 interaction attenuates BMP/Smad signaling in pulmonary hypertension by interfering with BMPR2/Caveolin-1 binding.	0
5	The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges. Volume 19, 103-126	0
4	Structural analysis of the P132L disease mutation in caveolin-1 reveals its role in the assembly of oligomeric complexes. 2023 , 299, 104574	0
3	Caveolae Mechanotransduction at the Interface between Cytoskeleton and Extracellular Matrix. 2023 , 12, 942	0
2	Pathophysiology and new advances in pulmonary hypertension. 2023 , 2, e000137	0
1	The building blocks of caveolae revealed: caveolins finally take center stage.	0